Transaction overview
Director Nikos Theodosopoulos of Hercules Capital, Inc. (NASDAQ: HTGC) purchased 7,317 shares of the companys common stock on March 26, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were acquired at an average price of $14.35, producing a total transaction value of $104,998. The individual trades were executed in a range between $14.31 and $14.39.
The purchase increases Theodosopoulos direct ownership to 29,362 shares of Hercules Capital. At the time the filing was noted, the stock was trading at $14.17, which is close to its 52-week low of $13.70, based on InvestingPro data.
Valuation signals and public metrics
Hercules Capital currently offers a dividend yield of 13.53% and reports a price-to-earnings ratio of 7.6. For investors seeking additional valuation and performance detail, a Pro Research Report covering HTGC is available through InvestingPro, which includes coverage for this company along with over 1,400 other U.S. equities.
Recent financial estimates
The company provided preliminary estimates for its fourth-quarter and year-end financials, projecting net asset value per share between $12.10 and $12.16 as of December 31, 2025. That range represents an increase from the $12.05 NAV per share reported at the end of September 2025.
Analyst action and external scrutiny
Piper Sandler revised its view on Hercules Capital, lowering its rating from Overweight to Neutral and cutting the price target to $17.50. The firm cited risks tied to artificial intelligence disruption within the software sector as a factor in its decision.
In addition, a short report from Hunterbrook questioned both the valuation of Hercules Capitals software-related debt and the sustainability of its dividends. Hunterbrook highlighted that approximately $1.5 billion of Hercules loan portfolio is exposed to software debt. The report noted that this portion of the portfolio is marked at full value despite what it described as industry-wide distress.
Credit amendment for Savara
Hercules Capital has amended a loan agreement with Savara Inc. The amendment enables Savara to obtain an additional $75 million in financing, contingent on Food and Drug Administration approval of its investigational therapy, MOLBREEVI. The amendment was disclosed as part of the companys recent activity updates.
What the filings and updates show
The combination of an insider purchase, a modest increase in estimated NAV, an analyst downgrade, and targeted scrutiny of software loan valuations provides a set of recent developments for shareholders to consider. The facts documented in regulatory filings and company disclosures outline the current position of Hercules Capital without projecting future outcomes.